206 related articles for article (PubMed ID: 27076751)
1. Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening.
Shi Z; Yu T; Sun R; Wang S; Chen XQ; Cheng LJ; Liu R
Pharmacogn Mag; 2016; 12(46):139-44. PubMed ID: 27076751
[TBL] [Abstract][Full Text] [Related]
2.
Shi Z; Chen J; Guo X; Cheng L; Guo X; Yu T
J Cancer Res Ther; 2018 Jan; 14(1):18-23. PubMed ID: 29516953
[TBL] [Abstract][Full Text] [Related]
3. Identification of anti-filarial leads against aspartate semialdehyde dehydrogenase of Wolbachia endosymbiont of Brugia malayi: combined molecular docking and molecular dynamics approaches.
Amala M; Rajamanikandan S; Prabhu D; Surekha K; Jeyakanthan J
J Biomol Struct Dyn; 2019 Feb; 37(2):394-410. PubMed ID: 29334340
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer.
Li J; Wang H; Li J; Bao J; Wu C
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27376283
[TBL] [Abstract][Full Text] [Related]
5. A novel identification approach for discovery of 5-HydroxyTriptamine 2A antagonists: combination of 2D/3D similarity screening, molecular docking and molecular dynamics.
Kumar R; Jade D; Gupta D
J Biomol Struct Dyn; 2019 Mar; 37(4):931-943. PubMed ID: 29468945
[TBL] [Abstract][Full Text] [Related]
6. 3D pharmacophore-based virtual screening, docking and density functional theory approach towards the discovery of novel human epidermal growth factor receptor-2 (HER2) inhibitors.
Gogoi D; Baruah VJ; Chaliha AK; Kakoti BB; Sarma D; Buragohain AK
J Theor Biol; 2016 Dec; 411():68-80. PubMed ID: 27693363
[TBL] [Abstract][Full Text] [Related]
7. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
[TBL] [Abstract][Full Text] [Related]
8. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
Mishra V; Pathak C
J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
[TBL] [Abstract][Full Text] [Related]
10. Identification of HER2 inhibitors from curcumin derivatives using combination of
Saibu OA; Singh G; Olugbodi SA; Oluwafemi AT; Ajayi TM; Hammed SO; Oladipo OO; Odunitan TT; Omoboyowa DA
J Biomol Struct Dyn; 2023; 41(21):12328-12337. PubMed ID: 36752338
[TBL] [Abstract][Full Text] [Related]
11. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
[TBL] [Abstract][Full Text] [Related]
12. Introducing a simple model system for binding studies of known and novel inhibitors of AMPK: a therapeutic target for prostate cancer.
Kumar R; Maurya R; Saran S
J Biomol Struct Dyn; 2019 Feb; 37(3):781-795. PubMed ID: 29447108
[TBL] [Abstract][Full Text] [Related]
13. Screening, Docking, and Molecular Dynamics Study of Natural Compounds as an Anti-HER2 for the Management of Breast Cancer.
Sohrab SS; Kamal MA
Life (Basel); 2022 Oct; 12(11):. PubMed ID: 36362883
[TBL] [Abstract][Full Text] [Related]
14. Integrating Ligand and Target-Driven Based Virtual Screening Approaches With
Tutumlu G; Dogan B; Avsar T; Orhan MD; Calis S; Durdagi S
Front Chem; 2020; 8():167. PubMed ID: 32328476
[TBL] [Abstract][Full Text] [Related]
15. Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2.
Balbuena-Rebolledo I; Padilla-Martínez II; Rosales-Hernández MC; Bello M
Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451888
[TBL] [Abstract][Full Text] [Related]
16. Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
Zeb A; Son M; Yoon S; Kim JH; Park SJ; Lee KW
Comput Struct Biotechnol J; 2019; 17():579-590. PubMed ID: 31073393
[TBL] [Abstract][Full Text] [Related]
17. Multiple e-pharmacophore modelling pooled with high-throughput virtual screening, docking and molecular dynamics simulations to discover potential inhibitors of Plasmodium falciparum lactate dehydrogenase (PfLDH).
Saxena S; Durgam L; Guruprasad L
J Biomol Struct Dyn; 2019 Apr; 37(7):1783-1799. PubMed ID: 29718775
[TBL] [Abstract][Full Text] [Related]
18. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
[TBL] [Abstract][Full Text] [Related]
19. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
Kalirajan R; Pandiselvi A; Gowramma B; Balachandran P
Curr Drug Res Rev; 2019; 11(2):118-128. PubMed ID: 31513003
[TBL] [Abstract][Full Text] [Related]
20. Design of peptidomimetics for inhibition of HER2 receptor dimerization by a combination of virtual screening, MD simulations, and QSAR in silico methods.
Jamalan M; Zeinali M; Barzegari Asadabadi E
Chem Biol Drug Des; 2013 Apr; 81(4):455-62. PubMed ID: 23006820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]